Market cap of Moderna Inc. [MRNA] reaches 93.09B – now what?

Related

Moderna Inc. [NASDAQ: MRNA] stock went on an upward path that rose over 1.68% on Monday, amounting to a one-week price decrease of less than -3.93%. The company report on November 15, 2021 that Health Canada Authorizes Booster Dose of Moderna’s COVID-19 Vaccine in Individuals 18 Years of Age and Older.

Moderna Inc., a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, confirmed that Health Canada authorized the use of a booster dose of the Moderna COVID-19 vaccine (SPIKEVAX™) at the 50 µg dose for individuals aged 18 and older administered at least six months after completion of the primary series.


3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free.

Sponsored


“We would like to thank Health Canada for this authorization and the Government of Canada for its continued confidence in our mRNA platform,” said Stéphane Bancel, Chief Executive Officer of Moderna. “We are grateful for the opportunity to provide Canadians with another layer of protection.”.

Over the last 12 months, MRNA stock rose by 162.97%. The one-year Moderna Inc. stock forecast points to a potential upside of 22.91. The average equity rating for MRNA stock is currently 2.70, trading closer to a bullish pattern in the stock market.

The market cap for the stock reached $93.09 billion, with 404.00 million shares outstanding and 366.54 million shares in the current float. Compared to the average trading volume of 13.71M shares, MRNA stock reached a trading volume of 5650775 in the most recent trading day, which is why market watchdogs consider the stock to be active.

Guru’s Opinion on Moderna Inc. [MRNA]:

Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for MRNA shares is $304.92 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on MRNA stock is a recommendation set at 2.70. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.

Wolfe Research have made an estimate for Moderna Inc. shares, keeping their opinion on the stock as Outperform, with their previous recommendation back on November 09, 2021. While these analysts kept the previous recommendation, Deutsche Bank raised their target price to Sell. The new note on the price target was released on October 22, 2021, representing the official price target for Moderna Inc. stock. Previously, the target price had yet another raise to $445, while Piper Sandler analysts kept a Overweight rating on MRNA stock. On August 06, 2021, analysts increased their price target for MRNA shares from 246 to 445.

The Average True Range (ATR) for Moderna Inc. is set at 19.63, with the Price to Sales ratio for MRNA stock in the period of the last 12 months amounting to 7.87. The Price to Book ratio for the last quarter was 9.38, with the Price to Cash per share for the same quarter was set at 22.49. Price to Free Cash Flow for MRNA in the course of the last twelve months was 8.18 with Quick ratio for the last quarter at 1.30.

MRNA Stock Performance Analysis:

Moderna Inc. [MRNA] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -3.93. With this latest performance, MRNA shares dropped by -27.49% in over the last four-week period, additionally plugging by 47.35% over the last 6 months – not to mention a rise of 162.97% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for MRNA stock in for the last two-week period is set at 29.42, with the RSI for the last a single of trading hit 26.58, and the three-weeks RSI is set at 32.94 for Moderna Inc. [MRNA]. The present Moving Average for the last 50 days of trading for this stock 350.37, while it was recorded at 231.58 for the last single week of trading, and 254.57 for the last 200 days.

Insight into Moderna Inc. Fundamentals:

Operating Margin for any stock indicates how profitable investing would be, and Moderna Inc. [MRNA] shares currently have an operating margin of -94.99 and a Gross Margin at +95.12. Moderna Inc.’s Net Margin is presently recorded at -92.99.

Return on Total Capital for MRNA is now -37.14, given the latest momentum, and Return on Invested Capital for the company is -36.66. Return on Equity for this stock declined to -39.99, with Return on Assets sitting at -16.74. When it comes to the capital structure of this company, Moderna Inc. [MRNA] has a Total Debt to Total Equity ratio set at 9.28. Additionally, MRNA Total Debt to Total Capital is recorded at 8.49, with Total Debt to Total Assets ending up at 3.24. Long-Term Debt to Equity for the company is recorded at 8.09, with the Long-Term Debt to Total Capital now at 7.41.

Reflecting on the efficiency of the workforce at the company, Moderna Inc. [MRNA] managed to generate an average of -$574,665 per employee. Receivables Turnover for the company is 1.13 with a Total Asset Turnover recorded at a value of 0.18.Moderna Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 1.30 and a Current Ratio set at 1.30.

MRNA Stock EPS

With the latest financial reports released by the company, Moderna Inc. posted -0.69/share EPS, while the average EPS was predicted by analysts to be reported at -0.35/share. When compared, the two values demonstrate that the company fail the estimates by a Surprise Factor of -97.10%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for MRNA. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Moderna Inc. go to 16.80%.

>> 7 Top Picks for the Post-Pandemic Economy <<

Moderna Inc. [MRNA] Insider Position Details

There are presently around $57,818 million, or 58.90% of MRNA stock, in the hands of institutional investors. The top three institutional holders of MRNA stocks are: BAILLIE GIFFORD & CO with ownership of 42,217,354, which is approximately -7.99% of the company’s market cap and around 1.90% of the total institutional ownership; VANGUARD GROUP INC, holding 27,181,411 shares of the stock with an approximate value of $6.39 billion in MRNA stocks shares; and BLACKROCK INC., currently with $6.32 billion in MRNA stock with ownership of nearly 38.634% of the company’s market capitalization.

Positions in Moderna Inc. stocks held by institutional investors increased at the end of November and at the time of the November reporting period, where 711 institutional holders increased their position in Moderna Inc. [NASDAQ:MRNA] by around 42,469,444 shares. Additionally, 387 investors decreased positions by around 25,512,795 shares, while 97 investors held positions by with 177,979,829 shares. The mentioned changes placed institutional holdings at 245,962,068 shares, according to the latest SEC report filing. MRNA stock had 317 new institutional investments in for a total of 4,183,001 shares, while 75 institutional investors sold positions of 962,057 shares during the same period.